NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Neximmune Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Neximmune Inc market cap is $100.00.
What is the 52-week high for Neximmune Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Neximmune Inc 52 week high is $1.01 as of October 10, 2025.
What is the 52-week low for Neximmune Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Neximmune Inc 52 week low is $0.00 as of October 10, 2025.
What is Neximmune Inc stock price today?
Neximmune Inc stock price today is $0.0001.
What was Neximmune Inc stock price yesterday?
Neximmune Inc stock price yesterday was $0.0001.
What is the 50-day moving average of Neximmune Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Neximmune Inc 50-day moving average is $0.0019.